The kindest cut: Excising the Patented Medicine Prices Review Board from the Canadian body politic
By Richard C. Owens, Rebecca Rosenberg, and Haya Sardar June 2, 2022 PDF of paper Executive Summary Canada’s drug price ...
By Richard C. Owens, Rebecca Rosenberg, and Haya Sardar June 2, 2022 PDF of paper Executive Summary Canada’s drug price ...
This article originally appeared in the Hamilton Spectator. By Nigel Rawson, February 23, 2022 Theatre of the Absurd features plays ...
With two years of COVID-19 experience and uncertainty around the omicron variant, it is clear that prompt access to new ...
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, ...
While unconstitutional institutions and policies may be accommodated by the provinces to some degree, pushing them too far will end ...
Canadians need Ottawa to work with the pharmaceutical industry, clinicians and patients to improve access to new medicines and vaccines, ...
OTTAWA, ON (June 18, 2020): The COVID-19 pandemic has revealed numerous weaknesses in Canadian health care, and as the world ...
OTTAWA, ON (June 2, 2020): Changes to the Patented Medicine Prices Review Board (PMPRB) have been delayed until January 2021 ...
Nothing fair exists in denying Canadian cystic fibrosis patients approved and funded access to treatments that they have been waiting ...
323 Chapel Street, Suite #300
Ottawa, Ontario
K1N 7Z2 Canada
613.482.8327
Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.
© 2021 Macdonald-Laurier Institute. All Rights reserved.